Empagliflozin antidiabetic drugs
systematic review meta-analysis network meta-analysis
 

Jardiance - BI-10773 - BI10773 - BI 10773      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultcardiovascular eventsCardiovascular death

diabetes type 2  

Kadowaki, 2013   empagliflozin -
Kadowaki , 2014     empagliflozin -
Ridderstrale, 2014        NCTempagliflozinGlimepiride + MET -
DeFronzo, 2015        NCTempagliflozinlinagliptin (add-on MET) -
Lewin, 2015      NCTempagliflozinlinagliptin (monotherapy) -
EMPA-REG OUTCOME, 2015      NCTempagliflozinplaceboLow risk of bias conclusive-14%-38%
EMPA-REG OUTCOME    NCTempagliflozinplacebo -
Barnett, 2014      NCTempagliflozinplacebo -
Ferrannini, 2013      NCTempagliflozinplacebo -
EMPA-REG MONO (Roden) vs placebo, 2013      NCTempagliflozinplacebo -
Kadowaki, 2015      NCTempagliflozinplacebo -
EMPA-REG PIO (Kovacs), 2013      NCTempagliflozinplacebo (add on MET+/-PIO) -
Rosenstock DOUBLON ???, 2013   empagliflozinplacebo (add-on INS) -
Rosenstock (1245.49), 2014      NCTempagliflozinplacebo (add-on INS+/-MET) -
Rosenstock, 2013      NCTempagliflozinplacebo (add-on MET) -
Ross, 2015     empagliflozinplacebo (add-on MET) -
EMPA-REG MET (Haring), 2014      NCTempagliflozinplacebo (add-on MET) -
Araki, 2015      NCTempagliflozinplacebo (add-on standard treatment) -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons